Mikkael Sekeres, MD, MS, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, discusses azacitidine monotherapy versus a combination with lenalidomide or vorinostat to treat myelodysplastic syndromes (MDS). This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.
Combination therapies with azacitidine for MDS
Теги
Speaker: Mikkael SekeresInstitution: Taussig Cancer InstituteEvent: MDS 2020Format: InterviewSubject: Myelodysplastic SyndromesMedicines: AzacitidineMedicines: LenalidomideMedicines: VorinostatMedicines: Checkpoint InhibitorsMedicines: AntibodiesField: TreatmentField: Trial UpdatesField: Clinical Practice
